Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry
Purpose
The purpose of this registry is to address optimal platelet inhibition during the early management of MI patients prior to coronary angiography or CABG.
Condition
- Myocardial Infarction
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
For the first 50 patients at each participating site, consecutive patients are entered in the registry if they are ≥ 18 years of age, underwent coronary angiography for a STEMI or NSTEMI, and received cangrelor at any time during the hospitalization or an oral P2Y12 inhibitor during his/her first 48 hours of the hospitalization for MI. Phase 2 Inclusion Criteria: Subsequent patients are eligible to be entered in the registry if they are ≥ 18 years of age and underwent coronary angiography for a STEMI or NSTEMI and meet at least 1 of the following criteria: 1. The patient was hospitalized for STEMI and met one of the following inclusion criteria: - The patient received cangrelor at any time during his/her hospitalization for MI. - The patient received an oral P2Y12 inhibitor during his/her first 48 hours of hospitalization AND either of the following: - The patient received a P2Y12 inhibitor and an opiate/opioid within 24 hours prior to or during primary PCI for STEMI presentation. OR - The patient underwent coronary angiography followed by CABG during the index MI admission and received any P2Y12 inhibitor within 7 days prior to CABG. 2. The patient was hospitalized for NSTEMI and met one of the following inclusion criteria: - The patient received cangrelor during his/her hospitalization for MI. - The patient received an oral P2Y12 inhibitor during his/her first 48 hours of hospitalization AND either of the following: - The patient underwent coronary angiography followed by CABG during the index MI admission and received any P2Y12 inhibitor within 7 days prior to CABG. OR - Any 2 of the following criteria without prior PCI or CABG: age> 60 years, male sex, diabetes, EF <40% prior heart failure
Exclusion Criteria
If the patient does not meet the inclusion criteria for either Phase.
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Case-Only
- Time Perspective
- Retrospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| STEMI/NSTEMI | Patients in the registry will be 18 years of age or older and underwent coronary angiography for a ST-elevation myocardial infarction (STEMI) or NSTEMI Non-ST-elevation myocardial infarction |
Recruiting Locations
Hyattsville, Maryland 20782
Syed Ali
More Details
- Status
- Recruiting
- Sponsor
- Chiesi USA, Inc.
Detailed Description
The CAMEO registry is a multicenter observational registry that will collect information on 4,000 patients with NSTEMI or STEMI treated with cangrelor or an oral P2Y12 inhibitor into the registry. Phase 1: Each site will abstract data from the medical record for the first 50 patients meeting the inclusion and exclusion criteria treated at the hospital within 4 months prior to study initiation or during the study period. Phase 2: After Phase 1, all cangrelor-treated patients meeting the inclusion and exclusion criteria treated at the hospital no later than 1 month from the discharge date will be entered into the registry, and we will begin sampling non-cangrelor patients in a 2:1 cangrelor: non-cangrelor ratio.